Sign In
Buy ASND
$238.59
+10.59 (+4.64%)
At Close: Jun 23, 2026
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
04:00pm, Saturday, 13'th Jun 2026
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with T
Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review
09:55am, Friday, 12'th Jun 2026
The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell Midcap Growth Index, for the quarter ended March 31, 2026. Among the top contributors to relati
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
04:01pm, Thursday, 11'th Jun 2026
– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatme
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
04:59pm, Monday, 08'th Jun 2026
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achon
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
12:16am, Thursday, 28'th May 2026
Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth,
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
01:01am, Saturday, 09'th May 2026
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma Reports First Quarter 2026 Financial Results
07:30am, Thursday, 07'th May 2026
- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ®
COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age a
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
04:01pm, Thursday, 30'th Apr 2026
COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thur
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
04:31pm, Tuesday, 21'st Apr 2026
COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Con
Assetmark Inc. Has $1.83 Million Stake in Ascendis Pharma A/S $ASND
03:24am, Tuesday, 21'st Apr 2026
Assetmark Inc. raised its holdings in Ascendis Pharma A/S (NASDAQ: ASND) by 48.1% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,579 sh
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
08:00am, Monday, 20'th Apr 2026
COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
12:00pm, Wednesday, 08'th Apr 2026
- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq
- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
04:01pm, Monday, 06'th Apr 2026
- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses
